|
Roching Holdings (SWX: RO), a Swiss developer of pharmaceutical and therapeutic medicines used in oncology, has agreed to acquire Ignyta (NASDAQ: RXRX), a US developer of personalized-medicine therapies designed for autoimmune diseases.
The $1.7 billion offer will allow Roche to execute on its strategy of fitting treatments to patients and to broaden its oncology portfolio globally. At $27 per share, the offer represents a 74% premium to Ignyta’s closing price on Thursday.
The deal is expected to close in the first half of 2018.
0 Comments
Leave a Reply. |
Archives
March 2019
Categories |
RSS Feed
|
|
|
Skyline Advisors is a division of Ideation Ventures, Inc. Services involving securities are offered through M&A Securities Group, Inc.4151 N Mulberry Drive Suite 252, Kansas City, MO, 64116 (“MAS") . Services involving real estate brokerage are offered through Berkshire Hathaway HomeServices Ambassador Real Estate ("BHHS"). Skyline, MAS, and BHHS are separate entities.
COPYRIGHT 2020. ALL RIGHTS RESERVED. |